
IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition
pharmafile | April 11, 2016 | News story | Medical Communications, Research and Development | Bristol-Myers Squibb, Gilead, HIV, anti-HIV
German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally lower benefit in comparison with the competition, according to an early benefit assessment.
The regulator has said the drug offered minor added benefit for pre-treated women, but not for men.
The drug is indicated if the previous treatment has failed or cannot be continued due to side effects.
The Federal Joint Committee (G-BA) said between four groups of patients depending on age (adolescents/ adults) and previous treatment (pre-treated/ treatment-naive). Genvoya was compared with efavirenz in combination with two other drugs in treatment-naive patients, and with individual antiretroviral therapy in pre-treated patients.
US drug major Bristol-Myers Squibb (NYSE: BMY) markets efavirenz under the brand name Sustiva in the US, the United Kingdom, Ireland, France, Germany, Italy, and Spain.
Anjali Shukla
Related Content

Long-acting therapies set to reshape HIV treatment market
The HIV treatment market is increasingly being shaped by therapies designed to reduce medication burden …

Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …






